Login to Your Account



Insmed Rattles Investors Despite Positive Phase III Data

By Staff Reports


Monday, July 1, 2013
Investors were less than impressed with the results from Insmed Inc.'s Phase III trial for Arikace, its liposomal amikacin for inhalation. The Monmouth Junction, N.J.-based company saw its shares (NASDAQ:INSM) plummet 18.7 percent, or $2.24, to close at $9.72 Monday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription